

NDA 021858/S-023

# SUPPLEMENT APPROVAL

Genentech Inc c/o Genentech, Inc. Attention: Sheila Ehrenberg Regulatory Agent 1 DNA Way South San Francisco, CA 94080

Dear Ms. Ehrenberg:

Please refer to your Supplemental New Drug Application (sNDA) dated and received July 23, 2021, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Boniva<sup>®</sup> (ibandronate) Injection.

This "Changes Being Effected in 30 days" supplemental new drug application provides for updated labeling in response to FDA's Supplement Request letter dated June 24, 2021.

### **APPROVAL & LABELING**

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling and with minor editorial revisions listed below and reflected in the enclosed labeling.

The revision date listed at the end of the Highlights of Prescribing Information and at the end of the Medication Guide has been updated to "01/2022" and "January 2022" respectively.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(I)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <a href="http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm">http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm</a>. Content of labeling must be identical to the enclosed labeling (text for the prescribing information, and Medication Guide) with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled *SPL Standard for Content of Labeling Technical Qs and As* at <a href="http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/GuidanceS/UCM072392.pdf">http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/GuidanceS/UCM072392.pdf</a>.

U.S. Food & Drug Administration Silver Spring, MD 20993 www.fda.gov NDA 021858/S-023 Page 2

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(I)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes, and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

## **CARTON AND CONTAINER LABELS**

Submit final printed carton and container labels that are identical to enclosed carton and container labels and carton and container labels submitted on July 23, 2021, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission "**Product Correspondence – Final Printed Carton and Container Labels for approved NDA 021858/S-023.**" Approval of this submission by FDA is not required before the labeling is used.

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Christopher LaFleur, Regulatory Business Process Manager, at (240) 402 - 4724.


Sincerely,

{See appended electronic signature page}

Ramesh Raghavachari, Ph.D. Chief, Branch 1 Division of Post-Marketing Activities I Office of Lifecycle Drug Products Office of Pharmaceutical Quality Center for Drug Evaluation and Research

Enclosures: Content of Labeling Carton and Container Labeling

U.S. Food & Drug Administration Silver Spring, MD 20993 www.fda.gov



(

Digitally signed by Ramesh Raghavachari Date: 1/11/2022 05:50:06PM GUID: 502d0913000029f375128b0de8c50020